Literature DB >> 2083219

Identification of a transcriptional unit adjacent to the breakpoint in the 14;19 translocation of chronic lymphocytic leukemia.

T W McKeithan1, H Ohno, M O Diaz.   

Abstract

The t(14;19)(q32.3;q13.1) is a recurring translocation found in the neoplastic cells of some patients with chronic lymphocytic leukemia (CLL). We have previously cloned the translocation breakpoint junction present in the leukemic cells from one such patient. In the present study, we have cloned and sequenced the breakpoint junction from a second patient. The breakpoint on chromosome 14 occurs within a switch region upstream of the immunoglobulin heavy chain C alpha 1 sequence. We detected a 2.1-2.3 kb transcript on Northern blots using a probe from chromosome 19 adjacent to this breakpoint. S1 nuclease protection experiments showed that transcription of the gene proceeds in a direction away from the breakpoint junction. This gene (for which we propose the name BCL3) may contribute to the malignant development of B-lymphocytes following the chromosome translocation. If so, it is the first protooncogene identified whose activation is principally associated with CLL.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2083219     DOI: 10.1002/gcc.2870010310

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  19 in total

1.  The BCL3 locus on chromosome 19 displays an informative microsatellite polymorphism.

Authors:  P H St George-Hyslop; H Ohno; J F Gusella; T McKeithan
Journal:  Nucleic Acids Res       Date:  1992-02-25       Impact factor: 16.971

2.  Molecular cloning of the breakpoints of a complex Philadelphia chromosome translocation: identification of a repeated region on chromosome 17.

Authors:  T W McKeithan; L Warshawsky; R Espinosa; M M LeBeau
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

3.  Constitutive expression of Bc1-3 in thymocytes increases the DNA binding of NF-kappaB1 (p50) homodimers in vivo.

Authors:  J H Caamaño; P Perez; S A Lira; R Bravo
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

Review 4.  Reappraisal of BCL3 as a molecular marker of anaplastic large cell lymphoma.

Authors:  Hitoshi Ohno; Momoko Nishikori; Yoshitomo Maesako; Hironori Haga
Journal:  Int J Hematol       Date:  2005-12       Impact factor: 2.490

5.  IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes.

Authors:  Hong Fang; Kaaren K Reichard; Kari G Rabe; Curtis A Hanson; Timothy G Call; Wei Ding; Saad S Kenderian; Eli Muchtar; Susan M Schwager; Jose F Leis; Asher A Chanan-Khan; Susan L Slager; Esteban Braggio; Stephanie A Smoley; Neil E Kay; Tait D Shanafelt; Daniel L Van Dyke; Sameer A Parikh
Journal:  Am J Hematol       Date:  2019-01-08       Impact factor: 10.047

6.  The proto-oncogene Bcl3 induces immune checkpoint PD-L1 expression, mediating proliferation of ovarian cancer cells.

Authors:  Yue Zou; Mohammad M Uddin; Sveta Padmanabhan; Yan Zhu; Pengli Bu; Ales Vancura; Ivana Vancurova
Journal:  J Biol Chem       Date:  2018-08-22       Impact factor: 5.157

7.  BCL3 encodes a nuclear protein which can alter the subcellular location of NF-kappa B proteins.

Authors:  Q Zhang; J A Didonato; M Karin; T W McKeithan
Journal:  Mol Cell Biol       Date:  1994-06       Impact factor: 4.272

8.  Bcl-3 acts as an innate immune modulator by controlling antimicrobial responses in keratinocytes.

Authors:  Amanda S Büchau; Daniel T MacLeod; Shin Morizane; Paul F Kotol; Tissa Hata; Richard L Gallo
Journal:  J Invest Dermatol       Date:  2009-03-12       Impact factor: 8.551

9.  High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis.

Authors:  Anne-Tove Brenne; Unn-Merete Fagerli; John D Shaughnessy; Thea Kristin Våtsveen; Torstein Baade Rø; Hanne Hella; Fenghuang Zhan; Bart Barlogie; Anders Sundan; Magne Børset; Anders Waage
Journal:  Eur J Haematol       Date:  2009-01-13       Impact factor: 2.997

10.  Impaired TNFalpha-induced A20 expression in E1A/Ras-transformed cells.

Authors:  H-L Huang; W-C Yeh; M-Z Lai; C Mirtsos; H Chau; C-H Chou; S Benchimol
Journal:  Br J Cancer       Date:  2009-10-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.